Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label phase 3 extension study of povetacicept in adults with IgA nephropathy
MOH_2026-09-30_017059Phase 3Active, not recruiting
- Sponsor
- Vertex Pharmaceuticals
- Start
- Sep 2026
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of povetacicept in IgA nephropathy (IgAN), sponsored by Vertex Pharmaceuticals. Primary endpoint: Long-term safety. Started Sep 2026; status: active, not recruiting.
02
Drugs
povetacicept
03
Conditions
IgA nephropathy (IgAN)
Beyond the preview
Go deeper on MOH_2026-09-30_017059.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2026-09-30_017059.